The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, and FANCL. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group B. Alternative splicing results in two transcript variants encoding the same protein.
^Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan M, Ling C, Rooimans MA, Bier P, Hoatlin M, Pals G, de Winter JP, Wang W, Joenje H (Oct 2004). "X-linked inheritance of Fanconi anemia complementation group B". Nat Genet36 (11): 1219–24. doi:10.1038/ng1458. PMID15502827.
Fei P, Yin J, Wang W (2006). "New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein". Cell Cycle4 (1): 80–6. doi:10.4161/cc.4.1.1358. PMID15611632.
Muller YA, Ultsch MH, de Vos AM (1996). "The crystal structure of the extracellular domain of human tissue factor refined to 1.7 A resolution". J. Mol. Biol.256 (1): 144–59. doi:10.1006/jmbi.1996.0073. PMID8609606.
Huang M, Syed R, Stura EA et al. (1998). "The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex". J. Mol. Biol.275 (5): 873–94. doi:10.1006/jmbi.1997.1512. PMID9480775.
Presta L, Sims P, Meng YG et al. (2001). "Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic". Thromb. Haemost.85 (3): 379–89. PMID11307801.
Faelber K, Kirchhofer D, Presta L et al. (2001). "The 1.85 A resolution crystal structures of tissue factor in complex with humanized Fab D3h44 and of free humanized Fab D3h44: revisiting the solvation of antigen combining sites". J. Mol. Biol.313 (1): 83–97. doi:10.1006/jmbi.2001.5036. PMID11601848.